Infliximab: a review of its use in the management of rheumatoid arthritis (Q33959133)

30 July 2017

1 reference

title

Infliximab: a review of its use in the management of rheumatoid arthritis (English)

1 reference

30 July 2017

1 reference

1

A Markham

0 references

author name string

A Markham

series ordinal

1

1 reference

30 July 2017

H M Lamb

series ordinal

2

1 reference

30 July 2017

publication date

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

59

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

1341-1359

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

30 July 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

The role of cytokines in rheumatoid arthritis. The Croonian Lecture 1995.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Building towards a consensus for the use of tumour necrosis factor blocking agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Review article: safety of infliximab in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Joint erosions and patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Access to disease modifying treatments for rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Etanercept: a review of its use in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

The Heberden Oration 1997. Treatment of rheumatoid arthritis: from symptomatic relief to potential cure.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Selection and use of laboratory tests in the rheumatic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10882166

12 December 2020

10.2165/00003495-200059060-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1030720854

0 references

1 reference